Publicacions
Articles científics publicats pels investigadors del Barcelonaβeta Brain Research Center (BBRC), relacionats amb la malaltia d'Alzheimer, la neuroimatge, la memòria i les malalties neurodegeneratives, entre altres camps.
-
Rodríguez-Fernández B, Vilor-Tejedor N, Arenaza-Urquijo EM, Sánchez-Benavides G, Suárez-Calvet M, Operto G, Minguillón C, Fauria K, Kollmorgen G, Suridjan I, de Moura MC, Piñeyro D, Esteller M, Blennow K, Zetterberg H, De Vivo I, Molinuevo JL, Navarro A, Gispert JD, Sala-Vila A, Crous-Bou M
Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study
Alzheimers Res TherAbstractTelomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer's disease (AD). We aimed to evaluate the potential causal role of...
-
Blackman J, Stankeviciute L, Arenaza-Urquijo EM, Suárez-Calvet M, Sánchez-Benavides G, Vilor-Tejedor N, Iranzo A, Molinuevo JL, Gispert JD, Coulthard E, Grau-Rivera O
Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults
Brain Commun.AbstractSleep abnormalities are prevalent in Alzheimer's disease, with sleep quality already impaired at its preclinical stage. Epidemiological and experimental data point to sleep abnormalities contributing...
-
Del Campo M, Peeters CFW, Johnson ECB, Vermunt L, Hok-A-Hin YS, van Nee M, Chen-Plotkin A, Irwin DJ, Hu WT, Lah JJ, Seyfried NT, Dammer EB, Herradon G, Meeter LH, van Swieten J, Alcolea D, Lleó A, Levey AI, Lemstra AW, Pijnenburg YAL, Visser PJ, Tijms BM, van der Flier WM, Teunissen CE
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels
Nat Aging.AbstractDevelopment of disease-modifying therapies against Alzheimer's disease (AD) requires biomarkers reflecting the diverse pathological pathways specific for AD. We measured 665 proteins in 797...
-
Luigi L, Silvia I, Viktor W, Wink AM, Mutsaerts HJ, Sven H, Kaj B, O'Brien JT, Giovanni FB, Gael C, Pierre P, Pablo ML, Adam W, Joanna W, Craig R, Gispert JD, Visser PJ, Philip S, Frederik B, Tijms BM
Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
Aging Brain.AbstractGray matter networks are altered with amyloid accumulation in the earliest stage of AD, and are associated with decline throughout the AD spectrum. It remains unclear to what extent gray matter...
-
Mofrad RB, Del Campo M, Peeters CFW, Meeter LHH, Seelaar H, Koel-Simmelink M, Ramakers IHGB, Middelkoop HAM, De Deyn PP, Claassen JAHR, van Swieten JC, Bridel C, Hoozemans JJM, Scheltens P, van der Flier WM, Pijnenburg YAL, Teunissen CE.
Plasma proteome profiling identifies changes associated to AD but not to FTD
Acta Neuropathol Commun.AbstractBackground: Frontotemporal dementia (FTD) is caused by frontotemporal lobar degeneration (FTLD), characterized mainly by inclusions of Tau (FTLD-Tau) or TAR DNA binding43 (FTLD-TDP) proteins. Plasma...
-
Poudevida S, de Sola S, Brugulat-Serrat A, Mas-Vall Llosera G, Castillo A, Huesa G, Piromalli D, Gramunt-Fombuena N
Effectiveness of a psychotherapeutic intervention group program in the improvement of caregiver well-being in Alzheimer's disease patients' family caregivers: the CuiDem study
Rev Neurol.AbstractIntroduction: Caregivers of patients with Alzheimer's Disease experience physical and emotional burnout that can be treated with non-pharmacological interventions.
Aim: Assess the efficacy of a group...
-
Chételat G, Lutz A, Klimecki O, Frison E, Asselineau J, Schlosser M, Arenaza-Urquijo EM, Mézenge F, Kuhn E, Moulinet I, Touron E, Dautricourt S, André C, Palix C, Ourry V, Felisatti F, Gonneaud J, Landeau B, Rauchs G, Chocat A, Quillard A, Devouge EF, Vuilleumier P, de La Sayette V, Vivien D, Collette F, Poisnel G, Marchant NL
Effect of an 18-Month Meditation Training on Regional Brain Volume and Perfusion in Older Adults: The Age-Well Randomized Clinical Trial
JAMA NeurolAbstractImportance: No lifestyle-based randomized clinical trial directly targets psychoaffective risk factors of dementia. Meditation practices recently emerged as a promising mental training exercise to...
-
Nosheny RL, Amariglio R, Sikkes SAM, Van Hulle C, Bicalho MAC, Dowling NM, Brucki SMD, Ismail Z, Kasuga K, Kuhn E, Numbers K, Aaronson A, Moretti DV, Pereiro AX, Sánchez-Benavides G, Sellek Rodríguez AF, Urwyler P, Zawaly K
The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations
Alzheimers Dement New YorkAbstractEfficient identification of cognitive decline and Alzheimer's disease (AD) risk in early stages of the AD disease continuum is a critical unmet need. Subjective cognitive decline is increasingly...
-
Argilés M, Sunyer-Grau B, Arteche-Fernandez S, Peña-Gómez C
Functional connectivity of brain networks with three monochromatic wavelengths: a pilot study using resting-state functional magnetic resonance imaging
Sci Rep.AbstractExposure to certain monochromatic wavelengths can affect non-visual brain regions. Growing research indicates that exposure to light can have a positive impact on health-related problems such as...
-
Akinci M, Sánchez-Benavides G, Brugulat-Serrat A, Peña-Gómez C, Palpatzis E, Shekari M, Deulofeu C, Fuentes-Julian S, Salvadó G, González-de-Echávarri JM, Suárez-Calvet M, Minguillón C, Fauria K, Molinuevo JL, Gispert JD, Grau-Rivera O, Arenaza-Urquijo EM
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?
Alzheimers Res TherAbstractBackground: The COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association...
